title: Myelodysplastic syndromes.
abstract: Myelodysplastic syndromes (MDS) represent a collection of stem cell disorders characterized by impaired hematopoiesis resulting in low peripheral blood counts. The majority of patients with MDS present with symptoms related to anemia; however, bleeding and infection are the most common causes of death. The median age of diagnosis is 72 and the median survival is 2.5 years. Lenalidomide, azacitidine, and decitabine are all FDA-approved agents to treat MDS; however, the only potential cure for MDS remains stem cell transplantation.
authors.affiliation: Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109, USA. bscott@fhcrc.org
authors.forename: Bart L
authors.initials: BL
authors.lastname: Scott
authors.forename: H Joachim
authors.initials: HJ
authors.lastname: Deeg
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents